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The aim of this paper is to compare a service offering genetic testing and presymptomatic surveillance to women at increased risk of
developing breast cancer with its predecessor of no service at all in terms of survival and quality-adjusted survival (QALYs) by means
of a Markov cohort chain simulation model. Genetic assessment and presymptomatic care provided between 0.07 – 1.61 mean
additional life years and 0.05 – 1.67 mean QALYs over no services. Prophylactic surgery and surveillance extended mean life
expectancy by 0.41 – 1.61 and 0.32 – 0.99 years, respectively over no services for high-risk women. Model outcomes were sensitive
to all the parameters varied in the sensitivity analysis. Providing cancer genetic services increase survival and as long as services do not
induce adverse psychological effects they also provide more QALYs. The greatest survival and QALY benefits were found for women
with identified mutations. As more cancer genes are identified, the survival and cost-effectiveness of genetic services will improve.
Although mastectomy provided most additional life years, when quality of life was accounted for oophorectomy was the optimal
strategy. Delayed entry into coordinated genetic services was found to diminish the average survival and QALY gains for a woman
utilising these services.
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Despite the recognition by clinicians for over a century that a
hereditary predisposition to cancer exists in certain families, the
possibility of utilising this information to help these patients has
only become available in the 1990s with the discovery of cancer
susceptibility genes (Steel et al, 1999). Two of the first common
cancer genes to be mapped and cloned were the breast and ovarian
cancer susceptibility genes BRCA1 (Miki et al, 1994) and BRCA2
(Wooster et al, 1995). It is estimated that BRCA1 and BRCA2 are
responsible for 5 – 10% of breast cancer cases (King et al, 1993;
Eeles, 1996) and 10% of ovarian cancer cases (Easton et al, 1993;
Couch and Weber, 1998; Landis et al, 1999; Risch et al, 2001).
Women with a BRCA1 mutation and multiple cases of BRCA1
mutations in their families can have a lifetime risk in excess of 80%
of developing breast cancer, a 40 – 60% chance of developing
ovarian cancer and possibly an increased risk of developing
colorectal cancer (Ford et al, 1994).
As a consequence of increased awareness of genetic issues and
the technology to test for mutations there has been demand for
genetic assessment services (Evans et al, 1994; Campbell et al,
1995; Priority Areas Cancer Team, 1998; Ponder, 1999), demand
that is likely to increase (Ponder, 1999). However, as cancer
mutations have only been isolated in the last decade, clinical trials,
cancer registry and observational studies will take years to collect
data, establishing long-term costs, and assess the efficacy of
surveillance and prophylactic interventions in preventing cancer
and prolonging life. In the mean time, researchers have begun to
look at these long-term outcomes by means of mathematical
modelling. Studies assessing the potential costs and benefits of
genetic testing accompanied by interventions for women free of
cancer but with a family history of breast and ovarian cancer
(Schrag et al, 1997; Grann et al, 1998, 1999a, 2000, 2002; Tengs et al,
1998; Tengs and Berry, 2000) found gains in life years for women
opting for bilateral prophylactic mastectomy and/or oophorect-
omy (Schrag et al, 1997; Grann et al, 1998, 2000, 2002) or
chemoprevention methods such as tamoxifen or raloxifene (not
available in the UK) (Grann et al, 2000, 2002) when compared with
presymptomatic surveillance alone.
In terms of assessing the survival advantages of providing
cancer genetic services to women at increased risk of breast
cancer the preceding studies have not addressed three important
issues. Firstly, despite varying the penetrance estimates (the
likelihood of developing cancer), they have confined their analysis
to BRCA1/2 mutation carriers only. However, the majority of
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history placing them at increased risk of developing breast
cancer do not have BRCA1/2 mutations. Most high-risk and all
moderate-risk families have as yet unidentified mutations.
Secondly, all women have been assumed to be at high risk of
developing both breast and ovarian cancer. However, the Cancer
Genetics Service in Wales referral guidelines, which were devel-
oped by means of a national multidisciplinary consensus group
meeting and GP focus groups, which are subject to ongoing
validation, segregate women according to their family history into
increased risk of developing breast cancer or breast and ovarian
cancer. This has implications both for the type of counselling to be
provided and the type of presymptomatic surveillance required.
Finally, none of these studies have compared the provision of
genetic services with the treatment as usual of no presymptomatic
services.
This paper stems from the work conducted by the GenQuest
research team who conducted a multimethod evaluation of the
Cancer Genetics Service in Wales. The aim of this paper is to
compare a service offering genetic testing and presymptomatic
surveillance to women at high and moderate risk of developing
breast cancer with its predecessor of no service at all. This will be
done by means of mathematical modelling, using available
epidemiological data and reasonable assumptions.
MATERIALS AND METHODS
Model design
A Markov cohort chain simulation model was developed and
run on Lotus 123 to estimate survival and quality-adjusted survival
for women at increased risk (high and moderate) of developing
breast cancer under the care of genetic services compared to
women receiving no such service. Three health states were
considered: good health, breast cancer and death (see Figure 1).
Additionally, the impact of regular mammography, bilateral
prophylactic mastectomy, prophylactic oophorectomy with regular
mammography or prophylactic mastectomy with oophorectomy
was accounted for in the simulated cohort receiving genetic
assessment services. Women were followed for a maximum 24
years (Markov cycles), starting at 35 years of age and terminating
at death or delayed entry into a national screening programme.
Transition between health states was assumed to occur annually.
Risk estimates of transition from one state to another were
transformed into annual transition probabilities by means of
the actuarial and the simple cumulative methods (Miller and
Homan, 1994).
Health parameters
Women are defined as being at increased risk of developing breast
cancer if they have one of the following four family histories on the
same side of the family; one, first-degree relative (sister, mother or
daughter) diagnosed with breast cancer at 40 years of age or less,
two, first-degree relatives diagnosed with cancer at 60 years of age
or less, three, first-or second-degree relatives (grandparent,
grandchild, uncle, aunt, nephew, niece or half-sibling) diagnosed
with breast cancer at any age or a first-degree relative with bilateral
breast cancer. Women at increased risk are segregated into high
and moderate risk using CYRILIC software. Women with a
heterozygote risk (chance of having a mutation) of less than 25%
are at moderate risk while those with a risk of 25% or more are at
high risk. An example of a high-risk family history would be a
woman with two first-degree relatives diagnosed with breast cancer
at 35 years of age. The genetic testing and presymptomatic
surveillance strategies modelled in this study are based upon those
used by the Cancer Genetics Service in Wales, a national cancer
genetics service (see Table 1). Both the health parameters that were
varied (see Table 2) and those held constant were derived from
peer review literature, national statistics and consultation with
epidemiologists.
Constant modelling parameters Half the offspring of BRCA1/2
mutation carriers will inherit their parents’ mutations (US
Department of Health & Human Services, 1999). A woman’s
likelihood of developing breast cancer was reduced by 90% by
having bilateral mastectomy (Ziegeler and Kroll, 1991; Hartmann
et al, 1997, 1999), reduced by 40% by having prophylactic
oophorectomy (Grann et al, 2002) and reduced by 91% by having
both surgeries (Tengs and Berry, 2000). All women dying from
breast cancer are assumed to have metastatic cancer for the last 12
months of their life. All-cause mortality for women was assumed to
be 0.26% annually (National Statistics, 2001). Of women receiving
annual mammography for 10 years or more, 0.01% will die
annually due to the radiation from mammography (National
Institute of Health Consensus Development Panel, 1997). Assum-
ing that two blood/DNA samples are analysed a false-negative rate
for presymptomatic BRCA1/2 tests would be expected to be less
than 0.01% (R Butler, personal communication, 2002).
Quality of life estimates
Life years were converted to quality-adjusted life years (QALYs) by
applying preference ratings. For the health states of bilateral
prophylactic mastectomy, prophylactic oophorectomy, having
both bilateral prophylactic mastectomy and oophorectomy, cancer,
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Figure 1 Markov state diagram.
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study of women aged 33 – 50 with a family history of breast and
ovarian cancer (Grann et al, 1999b). The preference ratings were
0.76 (s.d. 0.26) for bilateral prophylactic mastectomy, 0.82 (s.d.
0.27) for prophylactic oophorectomy, 0.73 (s.d. 0.25) for both
bilateral prophylactic mastectomy and prophylactic oophorect-
omy, 0.83 (s.d. 0.27) for cancer, 0.59 (s.d. 0.27) for metastatic
cancer and 0.0 for death. For presymptomatic women who had not
developed cancer yet and not opted to have a prophylactic surgery,
a study of women approaching the Cancer Genetics Service in
Wales for genetic assessment was conducted. Mean ratings for the
self-rated health status scale of the EuroQol EQ-5D (EuroQol
Group, 1990) were transformed to proportions for the 322 women
responding at baseline (approaching the service) and 124
responding postrisk assessment. The mean rating of 0.77 was very
similar to the findings of Grann et al (1999b) of 0.76 (s.d. 0.29).
Table 1 Care pathways
Genetic status Genetic service No genetic services
Low risk Reassured that they are at population risk. Enter national screening programme at 50 years
of age.
Enter national screening
programme at 50 years of age.
Moderate risk Phone counselling and regular mammography for women who wish to have
presymptomatic surveillance. Annual mammography from 40 to 50 and every 18 months
from 50 to 60 years of age. Women enter the national screening programme at 60 years of
age.
Enter national screening
programme at 50 years of age.
High risk – did not inherit a BRCA1/
2 mutation
Face-to-face counselling and genetic testing having found a BRCA1/2 mutation in a cancer-
affected relative. Informed that they are at population risk. Enter national screening
programme at 50 years of age.
Enter national screening
programme at 50 years of age.
High risk – inherited a BRCA1/2
mutation
Face-to-face counselling and genetic testing having found a BRCA1/2 mutation in a cancer-
affected relative. Women can then opt to have regular mammography, masteclomy,
oophorectomy and regular mammography or mastectomy with oophorectomy.
Surveillance is provided in the form of annual mammography from the age of 35–50 years
and every 18 months from 50 to 60 years of age. Women enter the national screening
programme at 60 years of age.
Enter national screening
programme at 50 years of age.
High risk – unknown mutation in
family
Face-to-face counselling but no genetic testing as a BRCA1/2 mutation was not found in a
cancer-affected relative. Women can then opt to have regular mammography, mastectomy,
oophorectomy and regular mammography or mastectomy with oophorectomy.
Surveillance is provided in the form of annual mammography from the age of 35–50 years
and every 18 months from 50 to 60 years of age. Women enter the national screening
programme at 60 years of age.
Enter national screening
programme at 50 years of age.
High-risk women that did not inherit a BRCA1/2 mutation and low-risk women are not included in the Markov model. The national screening programme is based upon the UK
breast screening programme providing mammography every 3 years from 50 years of age.
Table 2 Base-case probabilities and sensitivity analysis parameter estimates
Parameters High risk [sensitivity estimates]
Moderate risk [sensitivity
estimates]
Mutation prevalence 18% (Stoppa-Lyonnet et al, 1997) [7% (Couch et al, 1997; Stoppa-Lyonnet et al, 1997),
27% (Eccles et al, 1998)]
Mutation penetrance BRCA1/2 25%
a [17%, 33%]
c
82% (Easton et al, 1993) [70%
a, 82%]
Unidentified mutation
40%
a [35%, 40%]
a
Prophylactic mastectomy 5%
c [5%
c, 38%
d]0 %
c
Prophylactic oophorectomy 5%
c [0%
c, 14%
d]0 %
c
Prophylactic mastectomy and
oophorectomy
5%
c [0%
c, 13%
d]0 %
c
5 year death rate for genetics service
patients
35 – 54 years 7.8% – 2 year lead time [3.8% with no lead time, 9.4% with a 2 year lead
time]
b
35–54 years 7.8% – 2 year lead
time [3.8% with no lead time,
9.4% with a 2 year lead time]
b
55 – 59 years 11.5% – 2 year lead time [6.9% with no lead time, 16.7% with a 2 year lead
time]
b
55 – 59 years 11.5%-2 year lead
time [6.9% with no lead time,
16.7% with a 2 year lead time]
b
5 year death rate for nongenetics
service patients
35 – 54 years 28.4%
b [24.4%, 35.1%) – no lead time
b 35–54 years 28.4%
b [24.4%,
35.1%] – no lead time
b
55 – 59 years 34.9% [30.2%, 39.0%] – no lead time
b 55 – 59 years 34.9% [30.2%,
39.0%] – no lead time
b
Number of Markov cycles/years 24 [15, 24] 19 [9, 19]
aPDP Pharoah (personal communication, 2002).
bH Beer and H Fielder, Breast Test Wales (personal communication, 2002).
cEstimated by this research team.
dUp to 35 – 51%
of women at increased risk of developing breast cancer (Hatcher et al, 2001; Meijers-Heijboer et al, 2003) have been found to have prophylactic mastectomy and 27 – 49%
(Meijers-Heijboer et al, 2003; Schwartz et al, 2003) of women at increased risk of developing ovarian cancer have opted to have prophylactic oophorectomy. As this model deals
solely with women with a family history of breast cancer, we estimated that a maximum of 51% of women will have mastectomy (38% mastectomy alone +13% mastectomy and
oophorectomy) and 27% will have oophorectomy (14% oophorectomy alone +13% mastectomy and oophorectomy).
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As the benefits of cancer genetic services occur in the future these
benefits will be discounted. Discounting assumes that future
benefits are valued less than current benefits and allows
comparison of the benefits of programmes with differing time
profiles to be compared (Jones, 1997; Torgerson and Raftery,
1999). Quality-adjusted life years were discounted at 1.5% as
recommended by the National Institute of Clinical Excellence and
the Treasury (personal communication with NICE, 2002).
Sensitivity analysis
As there is uncertainty about many of the parameters associated
with genetic breast cancer (Easton et al, 1993, 1995; Ford et al,
1995; Couch et al, 1997; Serova et al, 1997; Stoppa-Lyonnet et al,
1997; Struewing et al, 1997; Whittemore et al, 1997; Eccles et al,
1998; Grann et al, 1999b), the uncertainty was accounted for by
conducting one-way and multi-way sensitivity analysis upon the
following model parameters:
 Prevalence of the mutation.
 Penetrance of the mutation.
 Percentage deciding to have bilateral mastectomy.
 The death rate of women receiving genetic services as survival
times for screen-detected cancers are artificially inflated by early
detection or lead time (Morrison, 1992).
 The death rate of women not receiving genetic services and
presymptomatic surveillance.
 Mean age of women entering the care pathways of the genetic service.
 QALY preference ratings.
 Discount rate.
Of all the women receiving mammography in a given year, 0.2%
of those with breast cancer will not be detected (H Beer & H Fielder
of Breast Test Wales, personal communication, 2002). The impact
of missed cancers by mammographic surveillance was assumed to
be negligible on the outcome measures of the modelling in the
base-case analysis. By conducting sensitivity analysis on the death
rates of women receiving and not receiving genetic services the
lead time and the efficacy of mammography and surgery are
accounted for.
UK population norms for the self-rated health status scores of
the EuroQol EQ-5D (Kind et al, 1999) were transformed to
proportions and used to simulate cancer genetic services increas-
ing, decreasing and causing no change in adverse psychological
effects relative to women receiving no genetic services. See Table 3
for the QALY parameter estimates. The discount rates applied were
0, 1.5 and 6%. All remaining parameter estimates are recorded in
Table 2.
RESULTS
Survival
The analysis revealed that genetic assessment followed by regular
presymptomatic surveillance provided greater life expectancy
than no health services, providing between 0.07 and 1.61
mean additional life years (see Table 4). Mean incremental life
expectancy increased for high-risk compared to moderate-risk
carriers and for high-risk BRCA1/2 mutation carriers compared to
high-risk carriers of unidentified mutations. Prophylactic oophor-
ectomy extended mean life expectancy over surveillance alone by
0.09–0.37 years and over no presymptomatic health services by
0.41 – 1.36 years. Bilateral prophylactic mastectomy or having
both bilateral prophylactic mastectomy and oophorectomy ex-
tended mean life expectancy over surveillance alone by 0.20–0.62
years and over no presymptomatic health services by 0.52–1.61
years.
Table 3 QALY parameter estimates
State Gen. services No gen. services
If equal adverse psychological effects (base case)
Cancer free 0.77 0.77
Prophylactic mastectomy 0.76 (Grann et al, 1999b) —
Prophylactic oophorectomy 0.82 (Grann et al, 1999b) —
Mastectomy and oophorectomy 0.73 (Grann et al, 1999b) —
Breast cancer 0.83 (Grann et al, 1999b) 0.83 (Grann et al, 1999b)
Metastatic cancer 0.59 (Grann et al, 1999b) 0.59 (Grann et al, 1999b)
Death 0.0 (Grann et al, 1999b) 0.0 (Grann et al, 1999b)
If gen. services creates adverse psychological effects
Cancer free 0.77 0.86 (Serova et al, 1997)
Prophylactic mastectomy 0.76 (Grann et al, 1999b) —
Prophylactic oophorectomy 0.82 (Grann et al, 1999b) —
Mastectomy and oophorectomy 0.73 (Grann et al, 1999b) —
Breast cancer 0.83 (Grann et al, 1999b) 0.83 (Grann et al, 1999b)
Metastatic cancer 0.59 (Grann et al, 1999b) 0.59 (Grann et al, 1999b)
Death 0.0 (Grann et al, 1999b) 0.0 (Grann et al, 1999b)
If gen. services reduce adverse psychological effects
Cancer free 0.77 0.68
a
Prophylactic mastectomy 0.76 (Grann et al, 1999b) —
Prophylactic oophorectomy 0.82 (Grann et al, 1999b) —
Mastectomy and oophorectomy 0.73 (Grann et al, 1999b) —
Breast cancer 0.83 (Grann et al, 1999b) 0.83 (Grann et al, 1999b)
Metastatic cancer 0.59 (Grann et al, 1999b) 0.59 (Grann et al, 1999b)
Death 0.0 (Grann et al, 1999b) 0.0 (Grann et al, 1999b)
aEstimated by the research team.
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Having adjusted survival to take account of quality of life, genetic
services were still found to provide additional life years with the
exception of women opting to have both bilateral prophylactic
mastectomy and oophorectomy. The hierarchy of QALYs gained
mirrored those found for unadjusted survival, except for women
having both mastectomy and oophorectomy, with most QALYs
being found for BRCA1/2 carriers (0.68–1.67 QALYs), followed by
high-risk carriers of unidentified mutations (0.05–1.21 QALYs)
and finally moderate-risk mutation carriers (0.05 QALYs). In
contrast to the findings for unadjusted survival, when quality of
life was accounted for the optimal clinical strategy was oophor-
ectomy with regular surveillance (1.21–1.67 QALYs), followed by
surveillance (0.21–0.68 QALYs), bilateral prophylactic mastectomy
(0.05–0.61 QALYs) and finally having bilateral prophylactic
mastectomy with oophorectomy (0.55–0.003 QALYs). Unlike
the alternative clinical strategies, oophorectomy with regular
surveillance recorded more incremental QALYs than unadjusted
survival. A result also found by Grann et al (2000, 2002). Despite
providing the greatest incremental survival, mastectomy and
having both mastectomy and oophorectomy provided less QALYs
than surveillance. In comparison to having no cancer genetic
services the clinical strategy of having both a mastectomy and an
oophorectomy provided almost no incremental QALYs for high-
risk BRCA1/2 mutation carriers (0.003 QALYs) and was inferior
for high-risk carriers of unidentified mutations (0.55 QALYs).
Sensitivity analysis
Both life years and QALYs were sensitive to all the parameters
varied in this study. Multi-way sensitivity analysis revealed that the
gain in mean life years from coordinated genetic services
compared to no services were at their maximum of 0.18 when
the parameter estimates were set at their most favourable (see
Tables 4 and 5). The minimum gain of 0.001 mean life years was
obtained for the least favourable parameter estimates (see Tables 4
and 5).
Applying a 0% discount rate to the base-case analysis provided
0.073 QALYs for the average woman attending cancer genetic
services. A 6% discount rate however resulted in only an additional
0.036 mean QALYs for these women. Changing the mean age of
women in the base-case analysis from 35 to 44 for high-risk women
and from 40 to 50 for moderate-risk women resulted in genetic
services only extending survival by 0.003 years or 1 day.
Varying QALY weightings for the base-case parameters resulted
in substantial change in the mean incremental QALY outcomes.
Substituting weightings indicative of reducing adverse psycholo-
gical effects among presymptomatic women (see Table 3) resulted
in genetic services giving a mean incremental QALY of 1.55
compared to no presymptomatic health services. In the event of
genetic services increasing adverse psychological effects compared
to no health services for presymptomatic women, the no health
services option provided 1.43 mean incremental QALYs over
genetic services.
DISCUSSION
The overall gains in survival and QALYs found in this study are
low, particularly for high-and moderate-risk carriers of unidenti-
fied mutations. However, quality of life was better for women that
were under the care of cancer genetic services with the exception of
women for who contact with genetic services would induce adverse
psychological effects and those women opting to have both
prophylactic mastectomy and oophorectomy.
In Table 4, the difference by risk status in the incremental
survival for women having presymptomatic care is a result of
mutation penetrance and the ability to identify mutation carriers.
Greater incremental survival is associated with higher mutation
penetrance or risk of developing breast cancer, the greater the
risk of death from cancer the greater the potential saving in
life years from surveillance and/or a health intervention. In the
autosomal dominant mode of transmission, half of the offspring
will be at risk for developing the disease. In the case of an
identified mutation such as BRCA1 or BRCA2, it is possible to
isolate the individuals inheriting the mutation and target them for
surveillance. As the high-risk unidentified mutations and moder-
ate-risk mutations have not been isolated yet, it is necessary to
extend presymptomatic surveillance to all members of such
Table 4 Mean incremental health outcomes of genetic services compared to no presymptomatic health services
Base case Least favourable Most favourable
Risk level and clinical strategy Life years QALYs Life years QALYs Life years QALYs
High-risk BRCA1/2 carriers
Genetic services 1.07 0.69 0.07 0.03 1.72 0.94
Surveillance 0.99 0.68 0.06 0.04 1.57 1.05
Mastectomy 1.61 0.61 0.23 0.06 1.83 0.76
Oophorectomy 1.36 1.67 — — 1.72 1.91
Mastectomy and oophorectomy 1.61 0.003 — — 1.83 0.15
High-risk carriers of an unidentified mutation
Genetic services 0.34 0.22 0.02 0.009 0.55 0.27
Surveillance 0.32 0.21 0.02 0.02 0.50 0.33
Mastectomy 0.52 0.05 0.08 0.11 0.59 0.10
Oophorectomy 0.41 1.21 — — 0.54 1.29
Mastectomy and oophorectomy 0.52 0.55 — — 0.59 0.51
Moderate risk
Genetic services 0.07 0.05 0.00 0.00 0.2 0.11
Surveillance 0.07 0.05 0.00 0.00 0.2 0.11
All at increased risk
Genetic services 0.09 0.06 0.001 0.0005 0.18 0.12
Life years were undiscounted and QALYs were discounted at 1.5%.
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by targeted use of presymptomatic surveillance for the two patient
groups.
Despite the clear advantage of the three prophylactic surgeries
over surveillance alone in terms of extending survival, this was not
the case when accounting for quality of life. The preference or
QALY weightings used in the current study reflect the fact that
although mastectomy and mastectomy with oophorectomy may
prevent the physical, social, psychological and economic impact of
living with cancer, it may also result in altered body image, a sense
of reduced femininity and physical discomfort from surgery
(Grann et al, 1998). There is also much uncertainty confronting
women having to make a decision about prophylactic surgery.
None of the prophylactic surgeries are 100% effective in preventing
cancer, not all mutation carriers will develop cancer and half of the
women from families with a known or unidentified mutation will
not inherit that mutation. Prophylactic surgery is likely to be most
appropriate for women with low concerns about the impact of
surgery upon their quality of life or for whom the impact of
surgery may be substantial but less severe than having to live with
the constant knowledge that they are at increased risk of
developing breast cancer.
The low incremental survival found for women who postponed
entry into the genetic service was a result of two factors. Firstly,
older women have less potential gains in life expectancy and less
time under the care of genetic service before entering conventional
surveillance at 60 years of age. Secondly, due to lack of data it has
been necessary to assume equal sensitivity for the 1–1.5 yearly
mammography for patients of the genetics service and three yearly
mammography provided to women receiving no presymptomatic
health services until they enter the national screening programme
at 50 years of age.
In comparison to the findings of Schrag et al (1997) and Grann
et al (1998, 2000, 2002), who recoded incremental survival of
between 2.8–5.3 life years for women having mastectomy, 0.8–2.6
years for oophorectomy and 4.3–7.6 years for mastectomy and
oophorectomy (Schrag et al, 1997; Grann et al, 1998, 2000, 2002)
compared to women having surveillance alone, the results for
BRCA1/2-positive women in the current study appear to be low.
There are three main reasons for this discrepancy. Firstly, Grann
et al ran their models for 50 (Grann et al, 1998, 2000) and 70
(Grann et al, 2002) cycles compared to the 24 used in the current
study. Secondly, Schrag et al (1997) and Grann et al (1998, 2000,
2002) used age-specific risk estimates of developing cancer based
upon the work of Struewing et al (1997). These estimates were not
utilised in the current study modelling health outcomes for the
general public as the Struewing et al (1997) work was based upon
the Ashkenazi Jewish population, an ethnic group known to have a
substantially higher prevalence of BRCA1/2 mutations than other
ethnic groups, 1.0–2.5% (Struewing et al, 1995; Oddoux et al, 1996;
Tonin et al, 1996) compared to 0.25–0.5% in the general public
(Brooks, 1999) and lower penetrance or lifetime risk (Ford et al,
1995; Struewing et al, 1997). Finally, Schrag et al (1997) and Grann
et al (1998, 2000, 2002) were modelling survival for women with a
BRCA1/2 mutation and a family history predisposing them to both
breast and ovarian cancer.
Table 5 Most and least favourable parameter estimates
Genetic services No presymptomatic services
Parameters High risk Moderate risk High risk Moderate risk
Most favourable
Mutation prevalence 27% — 27% —
Mutation penetrance 82% (BRCA1/2) 40%
(unidentified mutation)
33% 82% (BRCA1/2) 40%
(unidentified mutation)
33%
Prophylactic
mastectomy
38% 0% 0% 0%
Prophylactic
oophorectomy
14% 0% 0% 0%
Prophylactic
mastectomy and
oophorectomy
13% 0% 0% 0%
5 year death rate 35–54 years 3.8% with no lead
time
35–54 years 3.8% with no lead
time
35–54 years 35.1% with no lead
time
35–54 years 35.1% with no lead
lime
55–59 years 6.9% with no lead
time
55–59 years 6.9% with no lead
time
55–59 years 39.0% with no lead
time
55–59 years 39.0% with no lead
time
Number of Markov
cycles/years
24 19 24 19
Least favourable
Mutation prevalence 7% — 7% —
Mutation penetrance 70% (BRCA1/2) 35%
(Unidentified mutation)
17% 70% (BRCA1/2) 35%
(unidentified mutation)
17%
Prophylactic
mastectomy
5% 0% 0% 0%
Prophylactic
oophorectomy
0% 0% 0% 0%
Prophylactic
mastectomy and
oophorectomy
0% 0% 0% 0%
5 year death rate 35–54 years 9.4% with a 2 year
lead time
35–54 years 9.4% with a 2 year
lead time
35–54 years 24.4% with no lead
time
35–54 years 24.4% with no lead
time
55–59 years 16.7% with a 2
year lead time
55–59 years 16.7% with a 2
year lead time
55–59 years 30.2% with no lead
time
55–59 years 30.2% with no lead
time
Number of Markov
cycles/years
15 9 15 9
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lIt should be noted that chemoprevention methods have also
been modelled as presymptomatic interventions for women at
increased risk of developing breast and ovarian cancer due to
BRCA1/2 mutations. Compared to women having surveillance
alone raloxifene provided 2.2 incremental life years (Grann et al,
2000), tamoxifen 1.6–1.8 years (Grann et al, 2000, 2002) and
tamoxifen with oophorectomy 4.6 years (Grann et al, 2002). These
interventions were not considered in this study as they have not
been approved for use in the UK.
There are limitations to the current study which must be noted.
Firstly, in the absence of age-specific risk or penetrance estimates
of developing breast cancer, it was necessary to base annual
penetrance estimates upon lifetime risk estimates. Secondly, the
data upon mortality as a result of radiation from mammography
are based on estimates for women aged 40–49 years (National
Institute of Health Consensus Development Panel, 1997). It may be
that the risk varies considerably depending on the age at which
mammography commences and the duration of attendance for
women with a cancer genetic mutation. Thirdly, mortality
estimates are based upon the latest data available from Breast
Test Wales. However, this is based upon three yearly mammo-
graphy for women aged 50–59 who do not have a family history of
cancer. Depending upon how rapidly genetic cancer develops these
estimates may under-or overestimate the effectiveness of annual
mammography from 35/40 to 50 years and 18 monthly from 50 to
60 years for women with a family history of cancer. Fourthly,
cancer recurrence has not been accounted for. Fifthly, environ-
mental and lifestyle issues, and changes in these factors following
advice and information from the genetic service could not be
accounted for. Sixthly, as this study estimates incremental survival
a major patient group is excluded from the results of this analysis.
This group comprises of individuals from families with a known
BRCA1/2 mutation that have not inherited the mutation predis-
posing them to increased risk of developing cancer and for whom
the main outcomes are psychological. Finally, it has been proposed
that the wide range of positive and negative outcomes associated
with genetic testing such as reduced uncertainty or knowing that a
child has not inherited a mutated gene cannot be aggregated into a
single measure such as a QALY (Van der Riet et al, 1997). In the
future, as epidemiology for this patient group improves it will be
possible to rectify many of these limitations. Although several of
the above limitations would impact upon the differential in
survival and QALYs between genetic services and no such services
we do not envisage that the overall conclusions of the study would
change.
In conclusion, the results of the Markov modelling indicate that
providing women at increased risk of developing breast cancer
with cancer genetic services will give a small increase in their
estimated survival. As long as genetic services do not induce
adverse psychological effects they also provide greater quality of
life. The greatest survival and QALY benefits were found for
women with identified mutations such as BRCA1 or BRCA2. As
more cancer predisposing genes are identified, the survival
benefits and cost-effectiveness of genetic testing and presympto-
matic surveillance will improve for women at increased risk of
developing breast cancer. Although prophylactic mastectomy and
mastectomy with oophorectomy were found to be the most
effective in extending survival, when quality of life was accounted
for surveillance alone was a better option and oophorectomy
accompanied by regular surveillance was found to be the optimal
clinical strategy for the average woman. Delayed entry into
coordinated genetic services was found to diminish the average
survival and QALY gains for a woman utilising these services.
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